Page last updated: 2024-12-07
r 28935
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
R 28935: RN given refers to (R*,S*)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 93307 |
| MeSH ID | M0055871 |
Synonyms (7)
| Synonym |
|---|
| r 28935 |
| 55806-43-4 |
| 3-[1-[(2s)-2-(2,3-dihydro-1,4-benzodioxin-3-yl)-2-hydroxyethyl]piperidin-4-yl]-1h-benzimidazol-2-one |
| r-29814 |
| r 29814 |
| erythro-1-(1-(2-(1,4-benzodioxan-2-yl)-2hydroxyethyl)-4-piperidyl)-2-benzimidazolinone |
| 1-(1-((2s)-2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-2-hydroxyethyl)piperidin-4-yl)-1,3-dihydro-2h-benzo[d]imidazol-2-one |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "1-10 micrograms/kg) given through the left vertebral artery of chloralose-anesthetized cats, lowered blood pressure by a biphasic dose-response curve." | ( Central 5-HT1A receptors and the mechanism of the central hypotensive effect of (+)8-OH-DPAT, DP-5-CT, R28935, and urapidil. Boddeke, HW; Doods, HN; Hoyer, D; Kalkman, HO; Mathy, MJ; van Zwieten, PA, 1988) | 0.27 |
| ") there was a parallel shift to the right of the dose-response curve of R 28935 (v." | ( Centrally induced impairment of the hypotensive effects of R 28935 and R 29814 by prazosin in anaesthetized cats. Timmermans, PB; Van Zwieten, PA, 1980) | 0.74 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 10 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.05
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.05) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||